A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer
Status:
Recruiting
Trial end date:
2023-06-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out whether combining the standard chemotherapy for head
and neck cancer with the immunotherapy drugs cetuximab and cemiplimab (the study drug) is a
safe treatment for head and neck cancer, and whether receiving this combination treatment
before surgery may allow participants to forgo the standard radiation treatment after
surgery.